RZLTD Projected Dividend Yield

Rezolute Inc ( OTCBB : RZLTD )

Rezolute is a clinical stage biotechnology company developing therapies targeting rare and metabolic diseases. Co.'s primary pipeline, RZ358 is a fully human, monoclonal antibody that has been designed to treat all forms of Congenital Hyperinsulinism, as well as potentially other indications. RZ402 is a therapy for Diabetic Macular Edema and has been shown to normalize retinal vascular permeability in clinically-relevant animal models of macular edema. AB101 is an extended release microsphere formulation of PEGylated human recombinant insulin. It is being developed as a once-weekly subcutaneous injection to improve glycemic control in patients with Type 1 and Type 2 Diabetes Mellitus.

20 YEAR PERFORMANCE RESULTS